Protecting Patient Access to Cancer and Complex Therapies Act amends Medicare to require rebates from manufacturers for selected drugs and biological.
The Protecting Patient Access to Cancer and Complex Therapies Act amends Medicare provisions to ensure rebates from manufacturers for selected drugs and biological products. It specifies that manufacturers must pay rebates for selected drugs subject to maximum fair price negotiation. The bill also mandates that the Secretary of Health and Human Services report to manufacturers on selected drugs and requires manufacturers to provide rebates based on the negotiated maximum fair price. The rebates are in addition to any other required payments.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.